Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis

Abstract

Background

Observational series suggest a mortality benefit from metformin in the heart failure (HF) population. However, the benefit of metformin in HF with preserved ejection fraction (HFpEF) has yet to be explored. We performed a systematic review and meta-analysis to identify whether variation in EF impacts mortality outcomes in HF patients treated with metformin.

Methods

MEDLINE and EMBASE were searched up to October 2019. Observational studies and randomised trials reporting mortality in HF patients and the proportion of patients with an EF > 50% at baseline were included. Other baseline variables were used to assess for heterogeneity in treatment outcomes between groups. Regression models were used to determine the interaction between metformin and subgroups on mortality.

Results

Four studies reported the proportion of patients with a preserved EF and were analysed. Metformin reduced mortality in both preserved or reduced EF after adjustment with HF therapies such as angiotensin converting enzyme inhibitors (ACEi) and beta-blockers (β = − 0.2 [95% CI − 0.3 to − 0.1],  p = 0.02). Significantly greater protective effects were seen with EF > 50% ( p = 0.003). Metformin treatment with insulin, ACEi and beta-blocker therapy were also shown to have a reduction in mortality (insulin  p = 0.002; ACEi  p < 0.001; beta-blocker  p = 0.017), whereas female gender was associated with worse outcomes ( p < 0.001).

Conclusions

Metformin treatment is associated with a reduction in mortality in patients with HFpEF.